Reduction of Severity of Recurrent Psychotic Episode by Sustained Treatment with Aripiprazole in a Schizophrenic Patient with Dopamine Supersensitivity: A Case Report
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Dopamine supersensitivity psychosis (DSP) is a type of acute exacerbation of recurrent psychosis caused by long-term treatment with antipsychotics in schizophrenic patients. Although DSP is exceedingly troublesome for clinicians, effective treatment has not yet been established. Based on clinical research and our animal study, we hypothesize that aripiprazole, an atypical antipsychotic, may reduce the exacerbation of recurrent psychotic episodes. We report the case of a 46-year-old female who suffered from schizophrenia with DSP. In this case, sustained treatment with a high dose of aripiprazole gradually reduced the severity of her recurrent psychotic episodes. In conclusion, sustained treatment with aripiprazole may reduce the exacerbation of recurrent psychotic episodes in schizophrenic patients with DSP, and may be an effective treatment of DSP.
Abstract
Dopamine supersensitivity psychosis (DSP) is a type of acute exacerbation of recurrent psychosis caused by long-term treatment with antipsychotics in schizophrenic patients. Although DSP is exceedingly troublesome for clinicians, effective treatment has not yet been established. Based on clinical research and our animal study, we hypothesize that aripiprazole, an atypical antipsychotic, may reduce the exacerbation of recurrent psychotic episodes. We report the case of a 46-year-old female who suffered from schizophrenia with DSP. In this case, sustained treatment with a high dose of aripiprazole gradually reduced the severity of her recurrent psychotic episodes. In conclusion, sustained treatment with aripiprazole may reduce the exacerbation of recurrent psychotic episodes in schizophrenic patients with DSP, and may be an effective treatment of DSP.
참고문헌 (10)
- Chouinard G, "Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment", Schizophr Res, 5, pp.21~33 (1991)
- Chouinard G, "Atypical antipsychotics:CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes", Psychother Psychosom, 77, pp.69~77 (2008)
- Gorwood P, "Meeting everyday challenges: antipsychotic therapy in the real world", Eur Neuropsychopharmacol, 16(Suppl 3), pp.S156~S162 (2006)
- Croxtall JD, "Aripiprazole : a review of its use in the management of schizophrenia in adults", CNS Drugs, 26, pp.155~183 (2012)
- Tadokoro S, "Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis", Schizophr Bull, 38, pp.1012~1020 (2012)
- Montoya A, "Validation of the Excited Component of the Positive and Negative Syndrome Scale(PANSS-EC)in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room", Health Qual Life Outcomes, 9, pp.18~ (2011)
- Samaha AN, ""Breakthrough"dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time", J Neurosci, 27, pp.2979~2986 (2007)
- Iyo M, "Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis", J Clin Psychopharmacol, 33, pp.398~404 (2013)
- Di Lorenzo R, "Aripiprazole : effectiveness and safety under naturalistic conditions", Exp Clin Psychopharmacol, 15, pp.569~575 (2007)
- Takase M, "Dopamine supersensitivity psychosis and dopamine partial agonist : a retrospective survey of failure of switching to aripiprazole in schizophrenia", J Psychopharmacol, 29, pp.383~389 (2015)